NCT00856050View on ClinicalTrials.gov

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2014

Conditions
Leiomyosarcoma
Interventions
DRUG

letrozole

Taken orally once a day continuously

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00856050 - Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma | Biotech Hunter | Biotech Hunter